Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Addex Therapeutics
< Previous
1
2
Next >
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
April 29, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the Swiss Biotech Day 2024
April 19, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
April 18, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
April 11, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
April 03, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the Bio-Europe Spring 2024 Conference
March 14, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
January 31, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at the Swiss Equities Baader Conference
January 09, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex to Present at Biotech Showcase™ 2024
January 05, 2024
From
Addex Therapeutics
Via
GlobeNewswire
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
December 20, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Creates Treasury Shares
December 14, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
November 29, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Convenes Extraordinary General Meeting
November 28, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
November 23, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
November 14, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Regains Nasdaq Listing Compliance
November 08, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Announces Participation in the Bio-Europe 2023 Conference
November 02, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Completes ADS Ratio Change
October 20, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Announces Plan to Implement ADS Ratio Change
October 06, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
September 20, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
September 05, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
September 04, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 10, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
August 04, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
August 03, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
July 24, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Increases Issued Share Capital to Create Treasury Shares
June 15, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 01, 2023
From
Addex Therapeutics
Via
GlobeNewswire
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
May 18, 2023
From
Addex Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit